Antibody production: Polyclonalderived biotherapeutics

Abstract
Antibody based therapies using monoclonal or polyclonal antibodies are emerging as an important therapeutic approach for the treatment of a number of diseases. With increasing emphasis on new technologies associated with monoclonal antibody expression and purication, the clinical need of polyclonal therapeutics for treatment of a variety of specic illnesses and infections is often overlooked. Despite being largely abandoned in the early twentieth century due to the development of antibiotics, polyclonal antibody therapeutics are today widely used in medicine for viral and toxin neutralization and for replacement therapy in patients with immunoglobulin deciencies. Over the past 20 years, intravenous immunoglobulins have shown benecial immunomodulatory and anti-inammatory effects in many illnesses. Hyperimmune antibody preparations have been used over the past century for the treatment of a variety of infectious agents and medical emergencies, including digoxin toxicity, snake envenomation and spider bites. Here, we examine the contemporary techniques and applications, and assess the future therapeutic potential, for polyclonal-derived antibody therapeutics.

Antibodies play an important role in the defense against pathogens. They specically recognize and bind to foreign antigens, resulting in the activation of a number of immune effector functions capable of selectively eliminating foreign micro-organisms, viruses and molecules.

ANTIGEN-SPESIFIC RECOMBINANT POLYCLONAL ANTIBODIES

TECHNOLOGY TO DEVELOP NEXT G E N E R AT I O N P O LY C L O N A L A N T I B O D I E S . SYMPHOGEN(DENMARK) SYMPRESS SYMPRESS C U LT U R E USING MAMMALIAN CELL

TRANSGENIC POLYCLONAL THERAPEUTICS

LARGE-SCALE PRODUCTION OF P O LY C L O N A L ANTIBODIES USING ARTIFICIAL CHROMOSOME (HAC) TRANSGENIC PROCESS.
H A C C O N TA I N C H R O M O S O M E WITH ANTIBODY EXPRESSION.

HUMAN HUMAN WITH

22

NUMBER

H E M AT E C H L C C ( C O N N E C T I C U T, U S A ) C A LV E S ; T H E R A U P E T I C H U M A N P O LY C L O N A L S I N C . (CALIFORNIA, USA)RABBIT; O R I G E N T H E R A P E U T I C I N C ( U S A ) AV I A N EMBRYONIC

CELL.

POLYCLONAL ANTIBODIES FOR BIODEFENSE APPLICATIONS

C O M B AT B I O L O G I C A L W A R FA R E A G E N T S B Y M I M I C K I N G T H E PA S S I V E I M M U N I Z AT I O N . W I L L B E A D VA N TA G E O U S , B U T T H E R E R E S O M E FA C TO R S N E E D TO B E C O N S I D E R E D :

Immune response to a pathogen doesnt always correlate to protective immunity; Role of memory B cells in long term immunity often depends on the incubation period of pathogen.

OFFERING CLINICAL PROTECTION I M M E D I AT E LY A F T E R E X P O S U R E T O PAT H O G E N I C B A C T E R I A S O R V I R U S E S .

THE FUTURE OF POLYCLONAL ANTIBODY THERAPEUTICS

M O N O C L O N A L A N D P O LY C L O N A L ANTIBODIES.
N E O VA C S S A ( F R A N C E ) A N T I - C Y T O K I N E T H E R A P E U T I C S , T R E AT M E N T O F H I V. A D V A N T A G E S O F P O L Y C L O N A L A N T I B O D Y.